Processing...
All Trials
Search
Search
There are 1652 active trials in our database.
Click on a trial to see more information.
1652 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Enrolling adults with locally advanced or metastatic clear cell RCC (ECOG 0–1) previously treated with standard systemic therapy—dose escalation requires ≥2 prior regimens including immunotherapy and a targeted therapy, and expansion cohorts require prior exposure to both a PD-1/L1 inhibitor and a VEGF TKI. Participants receive oral BMS-986506 monotherapy (first-in-human small molecule; target/mechanism not publicly specified) with primary focus on safety/DLTs and secondary pharmacokinetics and preliminary RECIST activity.
ClinicalTrials.gov ID: NCT07195682
TrialFetch AI summary: For adults with locally advanced or metastatic unresectable clear cell renal cell carcinoma who have progressed on or declined standard therapies (ECOG 0–1, RECIST-measurable disease, eGFR ≥60, with available FFPE tumor tissue), this single-arm study evaluates escalating oral NEO-811 monotherapy given in 21-day cycles. NEO-811 is an investigational agent with an undisclosed molecular target/mechanism, assessed primarily for safety/tolerability and dose selection with preliminary RECIST activity.
ClinicalTrials.gov ID: NCT07300241
TrialFetch AI summary: Enrolls children/AYA age >12 months to <30 years with recurrent/refractory non-CNS solid tumors (dose-finding/expansion, including an HRR-altered cohort) and randomizes patients with first-relapse, EWSR1-rearranged Ewing sarcoma to compare efficacy. Treatment is nanoliposomal irinotecan (Onivyde; topoisomerase I–mediated DNA damage) on days 1 and 8 of 21-day cycles combined with either talazoparib (PARP1/2 inhibitor with PARP-trapping) or temozolomide (oral DNA-alkylating agent).
ClinicalTrials.gov ID: NCT04901702
TrialFetch AI summary: Enrolls adults with metastatic or locally advanced unresectable solid tumors (ECOG ≤2; measurable/evaluable by RECIST) with biologic rationale for RBM39 degradation; adolescents ≥16 may enroll for Ewing sarcoma or other supported malignancies, and stable treated brain metastases are allowed. Patients receive oral ST-01156, a small-molecule molecular glue RBM39 degrader (RNA-binding/splicing factor), dosed once daily on a 5-days-on/2-days-off schedule in 28-day cycles with dose escalation to define MTD/RP2D and assess early antitumor activity.
ClinicalTrials.gov ID: NCT07197554
TrialFetch AI summary: Adults with measurable metastatic uveal melanoma (ECOG 0–2), including heavily pretreated patients (HLA-A*02:01–positive patients generally expected to have received prior tebentafusp when available), are treated with NBM-BMX, an oral HDAC8-selective histone deacetylase inhibitor aimed at epigenetic modulation to promote tumor cell-cycle arrest and apoptosis. NBM-BMX is given as empty-stomach oral capsules twice daily in continuous 28-day cycles with dose escalation (100–400 mg BID) followed by expansion until progression or unacceptable toxicity.
ClinicalTrials.gov ID: NCT07136181
TrialFetch AI summary: Adults with unresectable locally advanced/metastatic EGFR-mutant NSCLC (ECOG 0–1) with progression after prior first- or second-line osimertinib (alone or with chemotherapy), excluding those with other actionable drivers or known EGFR osimertinib-resistance mutations. Treatment is continued osimertinib plus escalating-dose oral NXP900 (eCF506), a selective SRC-family kinase inhibitor (high potency vs YES1; also SRC) designed to lock kinases in an inactive conformation to address resistance biology.
ClinicalTrials.gov ID: NCT07315113
TrialFetch AI summary: Enrolls adults with ECOG ≤1 and advanced metastatic/unresectable HER2-expressing or HER2-amplified solid tumors lacking effective standard options, with an expansion cohort limited to platinum-resistant high-grade serous ovarian carcinoma (progression <6 months after last platinum) with HER2 IHC 1+ and a biopsy-accessible lesion. Patients receive trastuzumab deruxtecan (HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload) IV every 21 days plus oral olaparib (PARP inhibitor) twice daily on intermittent or continuous schedules.
ClinicalTrials.gov ID: NCT04585958
TrialFetch AI summary: Enrolling adults with advanced/unresectable, histologically confirmed high-grade serous ovarian, fallopian tube, or primary peritoneal carcinoma that is platinum-resistant (progression within 6 months) after standard therapies, limited to ≤5 prior lines and ≤2 regimens since becoming platinum-resistant. Patients receive IV ABBV-901 (investigational; target/mechanism not publicly specified) as monotherapy or combined with IV bevacizumab (anti-VEGF) in dose-escalation/expansion cohorts.
ClinicalTrials.gov ID: NCT07278336
TrialFetch AI summary: Enrolling adults with histologically confirmed high-grade serous ovarian, primary peritoneal, or fallopian tube cancer that is platinum-resistant (excluding primary platinum-refractory disease). Participants receive MEN2501 monotherapy, an oral small-molecule KIF18A (mitotic kinesin) inhibitor targeting chromosome alignment/spindle dynamics, with dose escalation followed by expansion to define RP2D and assess preliminary activity.
ClinicalTrials.gov ID: NCT07226427
TrialFetch AI summary: Enrolling adults with metastatic or unresectable, treatment-refractory solid tumors (ECOG ≤2, adequate organ and cardiac function), with a dose-expansion limited to pancreatic adenocarcinoma refractory/intolerant to all standard systemic options (including gemcitabine/nab-paclitaxel and fluoropyrimidine/oxaliplatin/irinotecan-based regimens). Patients receive TR-002, an investigational IV bisaminoquinoline “chemotherapy” agent with an unpublished/undisclosed mechanism, given as a 1-hour infusion weekly (days 1, 8, 15, 22 of each 28-day cycle) until progression or unacceptable toxicity.
ClinicalTrials.gov ID: NCT07189195